Atomoxetine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription non-stimulant medication approved for ADHD in children, adolescents, and adults. A selective norepinephrine reuptake inhibitor (NRI) that provides 24-hour symptom coverage without abuse potential. Particularly suitable for patients with comorbid anxiety, substance use disorders, or those who cannot tolerate stimulants. Takes 4–6 weeks for full therapeutic effect. Dosage must be determined by your prescribing physician.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription non-stimulant medication approved for ADHD in children, adolescents, and adults. NutriStack rates the supporting evidence as strong. Common adult dosing is 0.5–1.4 mg/kg/day in children; 40–100 mg daily in adults (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: adhd symptom improvement, no abuse or dependence potential, 24-hour symptom coverage. 10 sources indexed (2013–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Selectively inhibits the presynaptic norepinephrine transporter (NET) in the prefrontal cortex. Since dopamine reuptake in the prefrontal cortex is primarily mediated by NET (rather than DAT), atomoxetine also increases prefrontal dopamine levels. Does not significantly affect dopamine in the nucleus accumbens, accounting for its lack of abuse potential.
Dosing & protocol.
Can be taken with or without food. May be taken once daily in the morning or divided into morning and late afternoon doses. Do not open capsules.8
Full safety detail.
Side effects
- Decreased appetite
- Nausea
- Abdominal pain
- Fatigue
- Dizziness
- Mood swings
- Increased heart rate and blood pressure
- Dry mouth
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
4- 1Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-AnalysisPMIDdi Giacomo E, Confalonieri V, Tofani F et al. · JAMA network open · 2024
di Giacomo E, Confalonieri V, Tofani F et al.. Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis. JAMA network open. 2024
- 2Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and AtomoxetinePMIDHennissen L, Bakker MJ, Banaschewski T et al. · CNS drugs · 2017
Hennissen L, Bakker MJ, Banaschewski T et al.. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs. 2017
- 3The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetinePMIDPringsheim T, Hirsch L, Gardner D et al. · Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015
Pringsheim T, Hirsch L, Gardner D et al.. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2015
- 4Atomoxetine for treating ADHD symptoms in autism: a systematic reviewPMIDGhanizadeh A · Journal of attention disorders · 2013
Ghanizadeh A. Atomoxetine for treating ADHD symptoms in autism: a systematic review. Journal of attention disorders. 2013
Randomized controlled trials
2- 5Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity: A Randomized Crossover TrialPMIDMessineo L, Preuss M, Azarbarzin A et al. · Chest · 2025
Messineo L, Preuss M, Azarbarzin A et al.. Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity: A Randomized Crossover Trial. Chest. 2025
- 6Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trialPMIDMwesigwa N, Millar Vernetti P, Kirabo A et al. · Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2024
Mwesigwa N, Millar Vernetti P, Kirabo A et al.. Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. Clinical autonomic research : official journal of the Clinical Autonomic Research Society. 2024
Reference material
4- 7Cortese S et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018.Source linkedPMID
- 8Michelson D et al. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001.Source linkedPMID
- 9Gosling CJ et al. Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ. 2025.Source linkedPMID
- 10Schweitzer PK, Taranto-Montemurro L, Ojile JM et al.. The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial. American journal of respiratory and critical care medicine. 2023Source linkedPMID
Common questions.
Quick answers about Atomoxetine, drawn from the data on this page.
What is Atomoxetine?
Prescription non-stimulant medication approved for ADHD in children, adolescents, and adults. A selective norepinephrine reuptake inhibitor (NRI) that provides 24-hour symptom coverage without abuse potential. Particularly suitable for patients with comorbid anxiety, substance use disorders, or those who cannot tolerate stimulants. Takes 4–6 weeks for full therapeutic effect. Dosage must be determined by your prescribing physician.
What is Atomoxetine used for?
Commonly cited benefits of Atomoxetine include: ADHD symptom improvement; No abuse or dependence potential; 24-hour symptom coverage; Effective in comorbid anxiety; Not a controlled substance. NutriStack rates the overall evidence as strong.
What is a typical dose of Atomoxetine?
A typical adult dose of Atomoxetine is 0.5–1.4 mg/kg/day in children; 40–100 mg daily in adults (as prescribed by your physician). The commonly recommended form is Capsule. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Atomoxetine?
Reported side effects include decreased appetite, nausea, abdominal pain, fatigue, dizziness, mood swings. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Atomoxetine?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Atomoxetine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.